Ophthalmology - Luxturna™

Covered: one-time treatment (one subretinal injection per eye) with Luxturna for genetically confirmed biallelic RPE65 mutation–associated retinal dystrophy in patients aged ≥12 months and <65 years; re‑treatment of previously treated eyes and use in patients <12 months or ≥65 years (or outside these criteria) is excluded. Key requirements: must be given by a retinal specialist via subretinal injection (1.5×10^11 vg per eye) with the two eyes dosed ≥6 days apart, and documentation of genetic confirmation, viable retinal cells, age, provider, dosing/timing, and no prior Luxturna in the eye is required.

"Biallelic Human Retinal Pigment Epithelial 65 kDa Protein (RPE65) Mutation-Associated Retinal Dystrophy. Approve for one-time treatment course (i."

Sign up to see full coverage criteria, indications, and limitations.